Immunogenicity and safety of a new hexavalent rotavirus vaccine in Chinese infants: A randomized, double-blind, placebo-controlled phase 2 clinical trial

Immunogenicity and safety of a new hexavalent rotavirus vaccine in Chinese infants: A randomized, double-blind, placebo-controlled phase 2 clinical trial

Rotavirus remains a major cause of diarrhea among 5-y-old children, and vaccination is currently the most effective and economical measure. We conducted a randomized, double-blind, placebo-controlled phase II clinical trial designed to determine the dosage, immunogenicity, and safety profile of a no...

Full description

Bibliographic Details
Main Authors: Zhi-Wei Wu, Fei Jin, Qing-Liang Li, Jia-Mei Gao, Hai-Song Zhou, Kai Duan, Zhao Gao, Yan Liu, Zhi-Yong Hao, Wei Chen, Yue-Yue Liu, Ge-Lin Xu, Biao Yang, Ben Dong, Jiu-Wei Zhang, Yu-Liang Zhao, Xiao-Ming Yang
Format: Article
Language:English
Published: Taylor & Francis Group 2023-08-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
rotavirus
vaccine
safety
immunogenicity
Online Access:http://dx.doi.org/10.1080/21645515.2023.2263228

Internet

http://dx.doi.org/10.1080/21645515.2023.2263228

Similar Items